

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX INC.,
Petitioner

v.

NOVO NORDISK A/S,
PATENT OWNER

CASE IPR2024-00631
U.S. PATENT NO. 10,335,462
ISSUED: JULY 2, 2019

TITLE:
USE OF LONG-ACTING GLP-1 PEPTIDES
DECLARATION OF MARK J. RATAIN, M.D.

March 1, 2024

TABLE OF CONTENTS

	<u>Page</u>
TABLE OF CONTENTS	i
TABLE OF ABBREVIATIONS.....	v
I. QUALIFICATIONS AND BACKGROUND.....	1
II. LEGAL STANDARDS.....	7
III. PERSON OF ORDINARY SKILL IN THE ART.....	9
IV. BRIEF SUMMARY OF OPINIONS	10
V. THE '462 PATENT [Ex.1001].....	12
A. THE SPECIFICATION AND CLAIMS OF THE '462 PATENT.....	12
B. THE PROSECUTION HISTORY OF THE '462 PATENT	14
VI. CLAIM CONSTRUCTION.....	16
VII. BACKGROUND.....	18
A. PHARMACOKINETICS AND PHARMACODYNAMICS.....	18
B. DRUG DEVELOPMENT - CLINICAL TRIAL DESIGN	21
C. PHARMACOKINETICS AND PHARMACODYNAMICS RELATED TO GLP-1 AND SEMAGLUTIDE.....	28
1. GLP-1	28
2. GLP-1 derivatives	29
a. Liraglutide.....	32
b. Semaglutide	36
D. SEMAGLUTIDE CLINICAL TRIALS.....	37
VIII. SCOPE AND CONTENT OF THE PRIOR ART.....	40
A. WO421 [Ex.1011].....	42
B. LOVSHIN [Ex.1012].....	43
C. WO537 [Ex.1015]	45
D. SEMAGLUTIDE CLINICAL TRIALS.....	47
1. NCT657 [Ex.1013]	47

2.	NCT773 [Ex.1014]	49
3.	Public Availability of ClinicalTrials.gov	51
E.	KNUDSEN 2004 [Ex.1032]	57
F.	LUND [Ex.1035]	58
G.	SEINO [Ex.1038]	61
H.	VICTOZA LABEL [Ex.1039]	63
I.	SHARGEL [Ex.1045]	65
J.	TAMIMI [EX.1047]	66
K.	FDA EXPOSURE RESPONSE 2003 [EX.1048]	68
L.	ICH 1994 [Ex.1049]	70
M.	KNUDSEN 2010B [EX.1066]	72
N.	ADDITIONAL PRIOR ART AND REFERENCES	73
IX.	UNPATENTABILITY OF THE '462 PATENT	73
A.	GROUND 1: WO421 ANTICIPATED CLAIMS 1-3 OF THE '462 PATENT	73
1.	Teachings of WO421	73
2.	WO421 anticipated claim 1	73
3.	WO421 anticipated claim 2	79
4.	WO421 anticipated claim 3	79
B.	GROUND 2: LOVSHIN ANTICIPATED CLAIMS 1-3 OF THE '462 PATENT	80
1.	Teachings of Lovshin	80
2.	Lovshin anticipated claim 1	80
3.	Lovshin anticipated claim 2	83
4.	Lovshin anticipated claim 3	84
C.	GROUND 3: CLAIMS 1-10 OF THE '462 PATENT WOULD HAVE BEEN OBVIOUS OVER WO421	84
1.	Claim 1 would have been obvious over WO '421	84
a.	Teachings of WO421	85

b.	Skilled artisans would have been motivated to pursue, with a reasonable expectation of success, the treatment of type 2 diabetes with a once weekly 1.0 mg dose of semaglutide	85
2.	Claim 2 would have been obvious over WO '421	93
3.	Claim 3 would have been obvious over WO '421	93
4.	Claims 4-10 would have been obvious over WO '421 considering the '424 publication.....	94
D.	GROUND 4: CLAIMS 1-10 OF THE '462 PATENT WOULD HAVE BEEN OBVIOUS OVER WO537 CONSIDERING LOVSHIN	94
1.	Claim 1 would have been obvious over WO537 considering Lovshin.....	95
a.	Teachings of WO537 and Lovshin.....	95
b.	Skilled artisans would have been motivated to pursue, with a reasonable expectation of success, the treatment of type 2 diabetes with a once weekly 1.0 mg dose of semaglutide	95
2.	Claim 2 would have been obvious over WO537 considering Lovshin.....	103
3.	Claim 3 would have been obvious over WO537 considering Lovshin.....	104
4.	Claims 4-10 would have been obvious over WO537 considering Lovshin.....	105
E.	GROUND 5: CLAIMS 1-10 OF THE '462 PATENT WOULD HAVE BEEN OBVIOUS OVER NCT657 AND NCT773	105
1.	Claim 1 would have been obvious over NCT657 and NCT773.....	105
a.	Teachings of NCT657 and NCT773.....	106
b.	Skilled artisans would have been motivated to pursue, with a reasonable expectation of success, the treatment of type 2 diabetes with a once weekly 1.0 mg dose of semaglutide	106

2.	Claim 2 would have been obvious over NCT657 and NCT773.....	113
3.	Claim 3 would have been obvious over NCT657 and NCT773.....	114
4.	Claims 4-10 would have been obvious over NCT657, NCT773, and the '424 publication	115
F.	NO SECONDARY CONSIDERATIONS OVERCOME <i>PRIMA FACIE</i> OBVIOUSNESS OF THE CLAIMED ALLEGED INVENTIONS	115
1.	No unexpected results	115
2.	No long-felt, unmet need or skepticism.....	116
X.	CONCLUSION	116

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.